Phenex and Janssen: Research collaboration for autoimmune and chronic inflammatory disorders

20-Dec-2012 - Germany

Phenex Pharmaceuticals AG announced it has entered into an agreement with Janssen Biotech, Inc. and its affiliates to jointly discover compounds that target the nuclear hormone receptor RORγT and may have utility in the treatment of chronic autoimmune and inflammatory disorders including rheumatoid arthritis, psoriasis, and inflammatory bowel disease. Under the terms of the agreement Phenex will receive an upfront payment and milestone payments upon the achievement of specific development and regulatory events that could total as much as US$135 million. In addition, Phenex will also be eligible to receive tiered royalties and milestones on the worldwide sales of products that arise from the collaboration.

Researchers from Phenex and Janssen will work collaboratively towards the goal of identifying compounds that are active against RORγT and optimized for preclinical development. Thereafter, Janssen will have sole responsibility for the continued development and commercialization of any compounds that arise from the collaboration.

Other news from the department research and development

Most read news

More news from our other portals

All FT-IR spectrometer manufacturers at a glance